Skip to main content

Free Content Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic

Download Article:
 Download
(PDF 319.1884765625 kb)
 

Abstract:

SETTING: The Dominican Republic is a high-incidence area for multidrug-resistant tuberculosis (MDR-TB; 6.6% of initial cases). Standardised treatment regimens for MDR-TB may be a potential solution.

OBJECTIVE: To present the effectiveness of standard regimens under routine national conditions.

DESIGN: We reviewed all MDR-TB patients treated under routine conditions from 29 August 2006 to 30 June 2010, showing interim and final outcomes. Patients were treated with regimens that were standardised or individualised based on previously received second-line anti-tuberculosis drugs.

RESULTS: Population description and culture conversion data are reported for the 289 MDR-TB patients. The median patient age was 31 years. Most had failed first-line treatment (72.6%). Culture negativity was obtained within 4 months (median 2 months) in 78.6%. Among the 150 patients treated between 2006 and 2008, 74% had favourable results on standardised and 66% on individualised regimens (P = 0.211). The efficacy of the standardised and individualised regimens was respectively 92.8% and 81% (P = 0.056). The relapse rate was approximately 1%. A median of five drug side effects occurred per patient. More than 2 months to culture conversion and bilateral cavitation on chest X-ray were found to be unfavourable outcome risk factors.

CONCLUSIONS: Standardised MDR-TB regimens may be effective at the national level, even in resource-poor settings.

Keywords: Dominican Republic; MDR-TB; TB; multidrug-resistant tuberculosis; standardised treatment; tuberculosis

Document Type: Research Article

DOI: https://doi.org/10.5588/ijtld.12.0481

Affiliations: 1: Dominican Republic National Tuberculosis Programme, Santo Domingo, Dominican Republic 2: MDR-TB Unit, Department of Tuberculosis and HIV, International Union Against Tuberculosis and Lung Disease, Paris, France; and Departament de Pediatria, Ginecologia i Medicina Preventiva, Universitat Autònoma de Barcelona, Barcelona, Spain 3: MDR-TB Unit, Department of Tuberculosis and HIV, International Union Against Tuberculosis and Lung Disease, Paris, France; and Servicio de Neumología, Hospital General de Gran Canaria ‘Dr Negrin’, Las Palmas de Gran Canaria, Spain 4: Comité Nacional de Evaluación TB-MDR, Santo Domingo, Dominican Republic 5: Panamerican Health Organization, Washington DC, USA 6: Centros de Investigación Biomédica en Red de Epidemiología y Salud Pública, Barcelona, Spain; and Departament de Salut Pública, Universitat de Barcelona, Barcelona, Spain 7: Centros de Investigación Biomédica en Red de Epidemiología y Salud Pública, Barcelona, Spain

Publication date: 2013-04-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more